Cargando…
Eculizumab for refractory thrombosis in antiphospholipid syndrome
Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with antiphospholipid antibodies. Dysregulation of the complement pathway has been implicated in APS pathophysiology. We report the successful use of eculizumab, an anti-C5 monoclonal antibody, in controlling and p...
Autores principales: | Hussain, Habiba, Tarantino, Michael D., Chaturvedi, Shruti, McCrae, Keith R., Roberts, Jonathan C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864643/ https://www.ncbi.nlm.nih.gov/pubmed/35051999 http://dx.doi.org/10.1182/bloodadvances.2021005657 |
Ejemplares similares
-
Complement in the Pathophysiology of the Antiphospholipid Syndrome
por: Chaturvedi, Shruti, et al.
Publicado: (2019) -
Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab
por: Aberger, Simon, et al.
Publicado: (2023) -
A Case Report of COVID-Associated Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab
por: Chidharla, Anusha, et al.
Publicado: (2021) -
Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3
por: Zemke, Anna M, et al.
Publicado: (2021) -
Renal involvement and Strømme syndrome
por: Caridi, Gianluca, et al.
Publicado: (2020)